AN2 Therapeutics, Inc., (ANTX): Price and Financial Metrics


AN2 Therapeutics, Inc., (ANTX): $9.64

-0.31 (-3.12%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ANTX Stock Price Chart Interactive Chart >

Price chart for ANTX

ANTX Price/Volume Stats

Current price $9.64 52-week high $23.58
Prev. close $9.95 52-week low $6.88
Day low $9.35 Volume 38,000
Day high $10.21 Avg. volume 54,921
50-day MA $15.08 Dividend yield N/A
200-day MA $0.00 Market Cap 187.04M

AN2 Therapeutics, Inc., (ANTX) Company Bio


AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.


ANTX Latest News Stream


Event/Time News Detail
Loading, please wait...

ANTX Latest Social Stream


Loading social stream, please wait...

View Full ANTX Social Stream

Latest ANTX News From Around the Web

Below are the latest news stories about AN2 THERAPEUTICS INC that investors may wish to consider to help them evaluate ANTX as an investment opportunity.

Analysts Are Bullish on These Healthcare Stocks: AstraZeneca (AZN), Halozyme (HALO)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AstraZeneca (AZN – Research Report), Halozyme (HALO – Research Report) and AN2 Therapeutics, Inc. (ANTX – Research Report) with bullish sentiments. AstraZeneca (AZN) In a report released today, Andrew Berens from SVB Securities maintained a Buy rating on AstraZeneca, with a price target of $79.00. The company's shares closed last Friday at $62.77. According to TipRanks.

Catie Powers on TipRanks | November 14, 2022

AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

U.S. Enrollment Ongoing in EBO-301 Pivotal Phase 2/3 Clinical Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Plan to Include Japanese Patients in TrialAwarded Contract from NIAID Valued Up to $17.8 Million to Advance Development of Epetraborole for Acute Systemic Melioidosis MENLO PARK, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infecti

Yahoo | November 9, 2022

AN2 Therapeutics to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November. Details of the events are as follows: Stifel 2022 Healthcare Conference, November 15-17, 2022, New York, New York. Eric Easom, Co-Founder, President a

Yahoo | November 2, 2022

AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022

Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung Disease MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced one oral presentation and nine data poster presentations at the Infectious Disease Society of American (IDSA) IDWeek 2022 Conference from

Yahoo | October 19, 2022

AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese PatientsTreatment-Refractory MAC Lung Disease Clinical Development Strategy to Focus Initially on Japan and U.S., Two Countries with Highest Prevalence of MAC Lung DiseaseEpetraborole Granted Orphan Medicinal Product Designation in NTM Lung Disease in European Union MENLO PARK, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-

Yahoo | October 6, 2022

Read More 'ANTX' Stories Here

ANTX Price Returns

1-mo -39.52%
3-mo -24.57%
6-mo -26.97%
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6689 seconds.